Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens

摘要

Improved (safer and more effective) methods of therapy using TNF-R agonists,e.g., CD40 agonists are provided. These methods provide for the addition of anamount of a type 1 interferon and/or a TLR agonist that is effective to preventor reduce the toxicity (liver toxicity) that may otherwise result in some patientsof the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/rTLR agonist).